CLPTM1L expression predicts recurrence of patients with intermediate‑ and high‑risk stage IB‑IIB cervical cancer undergoing radical hysterectomy followed by TP as adjuvant chemotherapy.
adjuvant chemotherapy
cisplatin
cisplatin resistance-related protein 9
cleft lip and palate transmembrane protein 1-like protein
paclitaxel
uterine cervical cancer
Journal
Oncology letters
ISSN: 1792-1082
Titre abrégé: Oncol Lett
Pays: Greece
ID NLM: 101531236
Informations de publication
Date de publication:
Aug 2023
Aug 2023
Historique:
received:
10
04
2023
accepted:
14
06
2023
medline:
7
8
2023
pubmed:
7
8
2023
entrez:
7
8
2023
Statut:
epublish
Résumé
According to the National Comprehensive Cancer Network clinical practice guidelines of cervical cancer, concurrent chemoradiotherapy or radiotherapy is suggested for patients who receive radical hysterectomy and have intermediate- and high-risk cervical cancer. However, adjuvant chemotherapy has been increasingly chosen given the adverse events associated with chemoradiotherapy or radiotherapy and the increase in evidence regarding the efficacy of adjuvant chemotherapy. Given that adjuvant chemotherapy is not a standard treatment at present, if recurrence after adjuvant chemotherapy could be predicted, it would assist the decision of gynecological oncologists selecting which adjuvant therapy (chemotherapy or radiation therapy) to use. Cleft lip and palate transmembrane protein 1-like protein (CLPTM1L; also known as cisplatin resistance-related protein 9) is associated with apoptotic mechanisms and is related to the proliferation of the tumor cells and resistance against chemotherapy. In the present study, the association between CLPTM1L expression and recurrence of intermediate- and high-risk stage IB-IIB cervical cancer in patients undergoing radical hysterectomy followed by treatment with cisplatin and paclitaxel (TP) as adjuvant chemotherapy was determined. Patients were divided into two groups: Recurrence group and no-recurrence group. CLPTM1L expression was examined using immunohistochemistry in paraffin-embedded sections using weighted scores. Regarding the characteristics of the patients, a histology of non-squamous cell carcinoma, lymph node metastasis and parametrium invasion were more common in the recurrence group compared with the non-recurrence group. In the recurrence group, CLPTM1L expression was significantly higher than that in the no-recurrence group. Next, patients were divided into low and high-expression groups based on the weighted score with a cut-off value of 6. In the high expression group, patients exhibited a higher rate of recurrence (37.5 vs. 5.1%) and had worse overall survival. Multivariate analysis revealed that high CLPTM1L expression was independently related to recurrence. In
Identifiants
pubmed: 37545614
doi: 10.3892/ol.2023.13939
pii: OL-26-2-13939
pmc: PMC10398629
doi:
Types de publication
Journal Article
Langues
eng
Pagination
353Informations de copyright
Copyright: © Awazu et al.
Déclaration de conflit d'intérêts
The authors declare that they have no competing interests.
Références
J Gynecol Oncol. 2021 May;32(3):e44
pubmed: 33825359
Cancer Biomark. 2016;16(3):445-52
pubmed: 27062701
PLoS One. 2012;7(6):e36116
pubmed: 22675468
NPJ Precis Oncol. 2021 Mar 2;5(1):16
pubmed: 33654182
J Natl Compr Canc Netw. 2020 Jun;18(6):660-666
pubmed: 32502976
Int J Clin Oncol. 2019 Jan;24(1):1-19
pubmed: 30291468
Biochem Biophys Res Commun. 2001 Feb 2;280(4):1148-54
pubmed: 11162647
Mol Cancer Ther. 2016 May;15(5):985-97
pubmed: 26939707
Int J Cancer. 2019 Mar 15;144(6):1367-1378
pubmed: 30468251
Cancer Res. 2014 Feb 15;74(4):1116-27
pubmed: 24366883
Gynecol Oncol. 2018 Jun;149(3):513-519
pubmed: 29661497
Front Oncol. 2022 Mar 04;12:823064
pubmed: 35311123
Gynecol Oncol. 1996 Apr;61(1):3-10
pubmed: 8626113
Carcinogenesis. 2011 Oct;32(10):1493-9
pubmed: 21771723
J Obstet Gynaecol Res. 2008 Aug;34(4):552-6
pubmed: 18937708
PLoS One. 2013 Sep 13;8(9):e73837
pubmed: 24058496
Int J Cancer. 2016 Dec 15;139(12):2655-2670
pubmed: 27459707
J Obstet Gynaecol Res. 2023 Jun;49(6):1579-1591
pubmed: 36916196
Nat Genet. 2010 Nov;42(11):978-84
pubmed: 20972438
Nat Genet. 2010 Mar;42(3):224-8
pubmed: 20101243
CA Cancer J Clin. 2021 May;71(3):209-249
pubmed: 33538338
Front Med. 2023 Feb;17(1):93-104
pubmed: 36422763
BMC Cancer. 2022 Feb 23;22(1):202
pubmed: 35193525
Int J Cancer. 2012 Oct 1;131(7):1569-76
pubmed: 22213090
Cancer Res. 1995 Jan 15;55(2):237-41
pubmed: 7812951
Genet Mol Res. 2012 Feb 16;11(1):370-8
pubmed: 22370939
Mol Carcinog. 2012 Oct;51 Suppl 1:E118-22
pubmed: 22228261
Int J Mol Sci. 2018 Jul 24;19(8):
pubmed: 30042348
Curr Opin Oncol. 2000 Nov;12(6):543-9
pubmed: 11085453
Mol Clin Oncol. 2013 Jul;1(4):780-784
pubmed: 24649246
Melanoma Res. 2020 Apr;30(2):166-172
pubmed: 31626034
Int J Gynecol Cancer. 2021 Jul;31(7):991-1000
pubmed: 34016702
Cancer Res. 2014 May 15;74(10):2785-95
pubmed: 24648346
Methods. 2001 Dec;25(4):402-8
pubmed: 11846609
Adv Respir Med. 2020;88(6):485-494
pubmed: 33393640